362 related articles for article (PubMed ID: 25329698)
1. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.
Ardolino M; Azimi CS; Iannello A; Trevino TN; Horan L; Zhang L; Deng W; Ring AM; Fischer S; Garcia KC; Raulet DH
J Clin Invest; 2014 Nov; 124(11):4781-94. PubMed ID: 25329698
[TBL] [Abstract][Full Text] [Related]
2. Cytokines reinstate NK cell-mediated cancer immunosurveillance.
Zitvogel L; Kroemer G
J Clin Invest; 2014 Nov; 124(11):4687-9. PubMed ID: 25329691
[TBL] [Abstract][Full Text] [Related]
3. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I
Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144
[TBL] [Abstract][Full Text] [Related]
4. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
5. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
[TBL] [Abstract][Full Text] [Related]
6. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
Shklovskaya E; Rizos H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
[TBL] [Abstract][Full Text] [Related]
7. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
Neal ZC; Imboden M; Rakhmilevich AL; Kim KM; Hank JA; Surfus J; Dixon JR; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2004 Jan; 53(1):41-52. PubMed ID: 14504825
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
9. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I.
Draghi M; Yawata N; Gleimer M; Yawata M; Valiante NM; Parham P
Blood; 2005 Mar; 105(5):2028-35. PubMed ID: 15528315
[TBL] [Abstract][Full Text] [Related]
10. The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules.
Belicha-Villanueva A; Riddell J; Bangia N; Gollnick SO
Lasers Surg Med; 2012 Jan; 44(1):60-8. PubMed ID: 22246985
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Kijima M; Saio M; Oyang GF; Suwa T; Miyauchi R; Kojima Y; Imai H; Nakagawa J; Nonaka K; Umemura N; Nishimura T; Takami T
Int J Oncol; 2005 Mar; 26(3):679-84. PubMed ID: 15703823
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
Baxevanis CN; Gritzapis AD; Papamichail M
J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
[TBL] [Abstract][Full Text] [Related]
14. Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice.
Bélanger S; Tu MM; Rahim MM; Mahmoud AB; Patel R; Tai LH; Troke AD; Wilhelm BT; Landry JR; Zhu Q; Tung KS; Raulet DH; Makrigiannis AP
Blood; 2012 Jul; 120(3):592-602. PubMed ID: 22661698
[TBL] [Abstract][Full Text] [Related]
15. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours.
Seo H; Jeon I; Kim BS; Park M; Bae EA; Song B; Koh CH; Shin KS; Kim IK; Choi K; Oh T; Min J; Min BS; Han YD; Kang SJ; Shin SJ; Chung Y; Kang CY
Nat Commun; 2017 Jun; 8():15776. PubMed ID: 28585539
[TBL] [Abstract][Full Text] [Related]
16. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
17. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure.
Vredevoe DL; Widawski M; Fonarow GC; Hamilton M; Martínez-Maza O; Gage JR
Am J Cardiol; 2004 Apr; 93(8):1007-11. PubMed ID: 15081444
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility complex class I-independent killing of xenogeneic targets by rat allospecific natural killer cells.
Torgersen KM; Salcedo M; Vaage JT; Naper C; Rolstad B; Ljunggren HG; Höglund P
Transplantation; 1997 Jan; 63(1):119-23. PubMed ID: 9000672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
